Nexus Pharmaceuticals v. Nevakar & Endo: Ephedrine IV Patent Battle Closes After 907 Days
Nexus Pharmaceuticals asserted three patents covering its EMERPHED® ephedrine sulfate 5 mg/mL IV solution against Nevakar, Endo International, and Par Pharmaceutical in New Jersey federal court. The case ran for 907 days before termination, with the public record reflecting procedural sealing activity as the final docketed ruling.
Three-Patent IV Formulation Fight Ends Without Public Merits Ruling
On 23 September 2022, Nexus Pharmaceuticals, Inc. filed suit in the U.S. District Court for the District of New Jersey against Nevakar, Inc., Nevakar Injectables, Inc., Endo Ventures Ltd., Endo International PLC, Par Sterile Products LLC, and Par Pharmaceutical, Inc. Nexus alleged infringement of three patents — US11426369B2, US11571398B1, and US11464752B2 — each directed at ephedrine sulfate IV formulations. The accused products included Nevakar’s prefilled syringe product and, by extension, the downstream commercialisation chain involving the Endo and Par entities.
The case was formally terminated on 18 March 2025 after 907 days. The publicly available docket does not specify whether termination followed a settlement agreement, a voluntary dismissal, a consent judgment, or another mechanism. The last substantive ruling on record is a January 2025 order granting an unopposed motion to seal commercially sensitive regulatory and business strategy information — suggesting active litigation or negotiation was continuing close to the termination date.
A 907-day duration is consistent with cases that proceed through claim construction and discovery before resolving without a full trial, though the public record does not confirm this trajectory here. The sealing of business-sensitive correspondence in the final months suggests the parties may have been engaged in resolution discussions involving proprietary commercial terms. What drove the ultimate termination — and whether any licensing or commercial arrangement was reached — is not determinable from publicly available filings.
Filing to Case Terminated in 907 days
907 days — above the median for multi-defendant pharmaceutical patent cases in D.N.J.
Case terminated: what the public record does and does not reveal
Termination without a stated basis — what this means
A ‘Case Terminated’ entry without further specification means the docket was formally closed but the underlying mechanism — settlement, voluntary dismissal, consent order, or otherwise — is not publicly stated. It does not constitute a merits ruling. Either party could potentially have reserved rights depending on the actual resolution instrument, which may remain under seal.
No merits adjudication on recordNexus’s patent rights: unresolved in the public record
Because no invalidity or non-infringement finding was entered publicly, Nexus’s three ephedrine sulfate patents — US11426369B2, US11571398B1, and US11464752B2 — remain nominally intact and enforceable. The termination does not signal a litigation loss for Nexus, but equally does not confirm any damages award or injunctive relief. The strength of these patents against future entrants is unchanged by the case outcome alone.
Patents remain enforceableNevakar, Endo, and Par face ongoing IP uncertainty
The Endo and Par entities, along with Nevakar, avoided a public adverse judgment. However, the absence of a declared invalidity ruling means they cannot rely on this litigation as precedent clearing the asserted patents. Any continued or relaunched commercialisation of ephedrine sulfate prefilled syringe products would require independent FTO analysis against the Nexus patent family. The sealing of late-stage commercial strategy materials suggests terms may have been negotiated privately.
No public patent clearance obtainedIV formulation patent risk remains live for the sector
The case signals that Nexus is willing to assert its ephedrine sulfate formulation patents aggressively against both product developers and their commercialisation partners. With no public invalidity ruling, the Nexus patent family represents a standing litigation risk for any company developing or distributing competing IV ephedrine sulfate products, particularly in prefilled syringe formats targeted at hospital anaesthesia and critical care markets.
Formulation patents still in forceFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Nexus Pharmaceuticals, Inc. | Company | Pharmaceutical company — holder of US11426369B2, US11571398B1, and US11464752B2 covering EMERPHED® ephedrine sulfate IV solutionSearch in Eureka ↗ |
| Defendant | Nevakar, Inc. | Company | Nevakar, Endo International, Par Pharmaceutical, and related entities — developers and distributors of competing ephedrine sulfate prefilled syringe productsSearch in Eureka ↗ |
| Co-Defendant | Endo Ventures, Ltd. | Company | Search in Eureka ↗ |
| Co-Defendant | Nevakar Injectables, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Par Sterile Products, LLC | Company | Search in Eureka ↗ |
| Co-Defendant | Endo International, PLC | Company | Search in Eureka ↗ |
| Co-Defendant | Par Pharmaceutical, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Justin Taylor Quinn | Attorney | Counsel for Nexus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Robinson Miller LLC | Law Firm | Representing Nexus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Darren M. Geliebter | Attorney | Counsel for Nevakar, Inc.Search in Eureka ↗ |
| Defendant law firm | Lombard & Geliebter LLP | Law Firm | Representing Nevakar, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The most recent substantive ruling on public record is a procedural sealing order, not a merits determination. The court applied the D.N.J. Local Civil Rule 5.3 framework, finding that Defendants demonstrated good cause by showing disclosure of proprietary regulatory and commercial strategy materials would cause competitive injury. This ruling is significant context: it confirms that commercially sensitive negotiations or strategies were still live in January 2025, just weeks before the March 2025 case termination. It does not resolve infringement, validity, or damages.
US11426369B2, US11571398B1 & US11464752B2 — Ephedrine Sulfate IV Formulations
The three asserted patents — US11426369B2, US11571398B1, and US11464752B2 — cover ephedrine sulfate intravenous formulations, with application numbers indicating relatively recent grant dates in the early 2020s. The patents protect EMERPHED®, Nexus’s commercially approved 50 mg/10 mL (5 mg/mL) IV ephedrine sulfate solution. Ephedrine sulfate is a vasopressor agent used perioperatively to treat intraoperative hypotension, particularly in the context of spinal anaesthesia during caesarean delivery — a high-volume, high-acuity hospital segment.
These patents sit within a competitive segment where hospital formulary decisions favour ready-to-use prefilled formats over traditional vial-based preparation. Nevakar’s accused product — a 25 mg/5 mL single-dose prefilled syringe — directly targets the same clinical indication and hospital procurement channel. The three-patent assertion strategy suggests Nexus has layered its IP protection across formulation composition, method of use, and delivery format, creating multiple validity and infringement vectors that any competitor must navigate independently.
Should you run an FTO against US11426369B2, US11571398B1, and US11464752B2?
Any company developing, manufacturing, or distributing prefilled syringe or ready-to-use IV ephedrine sulfate products for the hospital anaesthesia market should treat this patent family as a live risk. The case termination without a public invalidity ruling means none of these patents has been adjudicatively cleared. EMERPHED’s market position in perioperative vasopressor therapy gives Nexus strong commercial incentive to continue enforcement against new entrants.
PatSnap Eureka’s FTO Search Agent allows R&D and regulatory teams to map their ephedrine sulfate formulation, concentration, and delivery format against each of the three Nexus patents in parallel. Eureka surfaces prior art, prosecution history, and claim scope analysis to help you identify design-around pathways or assess validity arguments before committing to clinical or commercial development in this product category.
Run a freedom-to-operate analysis on US11426369B2 to assess your product’s exposure
Run FTO in Eureka →Similar Injectable Pharmaceutical Patent Cases in D.N.J.
Explore related patent infringement cases involving IV formulation and prefilled syringe drug delivery patents litigated in the District of New Jersey.
Related patent case — similar technology
Comparable case in the same technology domain. Patent holder and defendant reached resolution after proceedings.
SettledRelated infringement action — same court
Comparable EMERPHED®, (ephedrine sulfate) 50mg/10ml (5 mg/mL) IV solution-adjacent infringement action. Patent enforcement dynamics analysed in depth.
Active · District CourtRelated invalidity challenge — appellate outcome
Combined invalidity and infringement action in the same technology space. Decided after substantive proceedings.
DecidedNexus Pharmaceuticals, Inc.’s broader IP enforcement history
Nexus Pharmaceuticals, Inc.’s full litigation history covering prior enforcement, licensing activity, and inter partes review proceedings.
Portfolio viewWhat this case signals for the injectable pharmaceutical IP landscape
A 907-day multi-defendant dispute over IV ephedrine formulations highlights the complexity of hospital-segment pharmaceutical patent enforcement.
Multiple downstream defendants signals a full-chain enforcement strategy
Nexus named not just the product developer Nevakar but also Endo and Par entities spanning manufacturing and distribution. This pattern — asserting patents against the entire commercialisation chain — is increasingly common in specialty pharmaceutical litigation and raises the litigation cost calculus for all parties involved.
Late-stage sealing of regulatory strategy documents is a resolution signal
The January 2025 order sealing proprietary regulatory and operational strategy materials, filed just weeks before case termination, is consistent with active settlement negotiation. Parties rarely seek to protect commercially sensitive strategy documents unless those terms are material to an imminent resolution.
Prefilled syringe format IP is a distinct risk layer for hospital procurement
The Nexus patents cover not just the ephedrine sulfate formulation but are asserted against a specific prefilled syringe delivery format — a product segment with rapid hospital adoption. Companies entering this delivery format should conduct targeted FTO analysis against the full Nexus portfolio before initiating clinical or commercial development.
Post-Endo restructuring creates counterparty uncertainty for licensing outcomes
Endo International filed for bankruptcy restructuring during the broader period of this litigation. Any licensing or settlement terms negotiated with Endo entities may face complications in enforcement or transferability. Parties monitoring this dispute for precedent should verify the current status of Endo successor entities before drawing commercial conclusions.
Nexus v Nevakar — key questions answered
Nexus asserted three patents: US11426369B2, US11571398B1, and US11464752B2. All three cover ephedrine sulfate intravenous formulations associated with EMERPHED®, a 50 mg/10 mL (5 mg/mL) IV solution approved for perioperative vasopressor use.
The public record reflects only ‘Case Terminated’ without specifying the mechanism. The docket does not confirm settlement, voluntary dismissal, or merits adjudication. The last substantive ruling was a January 2025 sealing order protecting proprietary regulatory and commercial strategy materials, suggesting a private resolution is possible but unconfirmed.
Yes. No invalidity or non-infringement ruling was entered on the public record. US11426369B2, US11571398B1, and US11464752B2 remain in force. Companies developing competing ephedrine sulfate IV or prefilled syringe products should conduct independent FTO analysis against this patent family.
Nexus adopted a full-chain enforcement approach, naming both the product developer (Nevakar and Nevakar Injectables) and downstream commercial partners including Endo and Par entities. This is consistent with pharmaceutical patent litigation strategy that targets all parties in the distribution and commercialisation chain to maximise damages exposure and leverage.
EMERPHED® is Nexus Pharmaceuticals’ FDA-approved ephedrine sulfate 5 mg/mL intravenous solution, indicated for the treatment of clinically important hypotension during anaesthesia. It is ready-to-use and primarily used perioperatively. The accused Nevakar product — a 25 mg/5 mL prefilled syringe — targets the same hospital anaesthesia market segment, making direct competition and patent conflict commercially significant.
Track IV formulation patent risk before your next product decision
Use PatSnap Eureka to monitor the Nexus ephedrine sulfate patent family for continuations, IPR filings, or new enforcement actions. Run an FTO before committing to clinical or commercial development in the hospital IV vasopressor segment.
PatSnap Eureka searches patents and litigation data to answer instantly.